Excessive weight gain occurred in a patient who was taking sodium valproate and phenytoin.
hyperglycinuria,52 hyperammonaemia," sedation,5 alopecia,5 and tremor. 7 Though excessive weight gain is a recognised side effect of sodium valproate, it has not been studied in detail. In the recent data sheet on Epilim (January 1981) it is dismissed as "Increase in alertness, appetite and weight may occur." We analysed retrospectively 100 children whose epilepsy was treated with sodium valproate to determine the frequency and amount of weight gain and any association between excessive weight gain and the type of epilepsy or the degree of control of fits.
Patients and methods
The patients were an unselected group from the neurology clinics of two children's hospitals. There were 40 boys and 60 girls, and their ages ranged between 15 months and 18 years.
Treatment-The daily dosage of sodium valproate was 30-50 mg/kg body weight. The duration of treatment was between six months and five years, and altogether the drug had been taken for a total of 205 patient-years. Eighty-five of the patients had been taking other anticonvulsants before starting sodium valproate and served as their own controls; 45 required other anticonvulsants in addition to sodium valproate. Weight-velocity charts of Tanner and Whitehouse14 showed that the yearly weight velocity, which had been within normal limits during the year before sodium valproate was introduced, exceeded or reached the 98th centile in 38 children during the year after the drug was started. (In a normal population only 3o% of children are expected to reach or exceed the 98th centile.) In another six children the weight BRITISH MEDICAL JOURNAL VOLUME 283 29 AUGUST 1981 velocity increased but remained within normal limits. Boys and girls were similarly affected (fig 1) .
Using the growth and development charts of Tanner et al, 5 we found that weight had increased by one centile in 25 patients, by two centiles in 13, by three centiles in four, and by four centiles in two. No increase in height velocity was seen. Because of continuing weight gain sodium valproate was withdrawn in three children. Figure 2 shows the patterns of increased weight gain. There was no obvious correlation between control of fits and excessive weight gain. Thirteen of all 24 patients who became fit free were affected, as were 15 of the 28 whose fit frequency decreased by more than 50'0, nine of the 25 whose fit frequency decreased by less than 5000, six of the 21 who did not improve, and one patient whose epilepsy had deteriorated.
Types of epilepsy among 100 children and outcome of treatment with sodium valproate (percentages in parentheses) Result Of the 85 patients who had been taking other drugs before starting sodium valproate, none showed a comparable increase in weight related to introducing or stopping drugs. Smaller changes in appetite and weight were related to alterations in phenytoin-induced gum swelling.
Gastrointestinal disturbances
Nausea, vomiting, diarrhoea, or abdominal pain occurred in 20 patients. Such disturbances were transient when treatment was started in a low dose and increased gradually, but in some patients given a high dose initially it was necessary to reduce the dose and increase it slowly, after which it was usually tolerated. Abdominal pain was, however, severe in four patients and necessitated stopping the drug in three.
Gastrointestinal disturbances led to loss of weight in 11 children. Five of these gained excessive weight after the gastrointestinal symptoms disappeared. In three others weight returned to the original channel after improvement in the gastrointestinal symptoms; and in the remaining three, in whom these symptoms required stopping sodium valproate, weight returned to normal.
Nocturnal enuresis
This occurred in seven patients and stopped without treatment after a few months.
Effect on hair
Transient hair loss was seen in six patients; and in three the hair became noticeably curly, especially in the frontal region. Microscopical examination of hair from two of these patients showed no abnormality.
Other side effects
Severe lassitude was reported in nine children and aggressive behaviour in four others. Since there was no apparent improvement in their epilepsy the drug was withdrawn. Poor appetite was noted in the patients who suffered severe lassitude during treatment, and four of them also lost weight. After stopping the drug all these symptoms disappeared.
There were no signs or symptoms of hepatic, pancreatic, or haematological disorder, and laboratory tests for these were therefore not performed.
Discussion
Apart from hormones no other drugs are known to cause increased appetite and weight gain. The mechanism(s) by which sodium valproate does this and the reason why some patients do gain weight while others do not are not understood.
A partially controlled limbic or temporal lobe phenomenon seems unlikely, since all types of epilepsy were affected in our series, and the degree to which fits were controlled had no influence. A direct effect of sodium valproate or a metabolite on the hypothalamus is more likely since small doses of the drug did not affect weight, whereas doses higher than 25-30 mg/kg did. Other workers (P M Jeavons, personal communication, 1981) believe that weight gain is unrelated to dose.
Some neurons in which gamma-aminobutyric acid is the transmitter substance and which inhibit pacemaker neurons are themselves inhibited by neurons activated by that agent, resulting in disinhibition. 16 In some patients sodium valproate may disturb the balance between inhibiting and disinhibiting neurons activated by gamma-aminobutyric acid by increasing disinhibition, so causing deterioration in epilepsy or nocturnal enuresis or increased appetite.
Obese patients have decreased activity of Na+ and K+ adenosine triphosphatase in red blood cells.'7 A similar defect is thought to occur in all cell types in man as in the ob ob mouse.'8 Bondy'9 speculated that the resulting decreased cellular thermogenesis could be the cause of the increased appetite. Sodium valproate increases the membrane stability by increasing K+ and C1-conductance,3 and it may be postulated that less adenosine triphosphatase is needed for repolarisation, causing reduced thermogenesis. The resulting minor temperature changes in the hypothalamus may also explain increased appetite during treatment with sodium valproate. Gastrointestinal side effects may be due to a direct effect on the gut. They are rarer with the enteric-coated preparation. That they appear to be commoner in the USA may be due to the wider use there of valproic acid rather than sodium valproate.
There are important clinical implications of the excessive weight gain and increased appetite caused by sodium valproate. Two of our patients were diabetics; fortunately their weight and appetite were not affected. One girl, aged 13, who became obese while taking sodium valproate developed meralgia paraesthetica, which is very rare in childhood.20 Another patient taking sodium valproate and phenytoin developed phenytoin intoxication after the sodium valproate was stopped because of a gain of 30 kg over six months. He lost 15 kg within a few weeks, and phenytoin, which had been adjusted for his increased weight, caused intoxication. With other drugs, such as digoxin, a similar sequence of events could cause serious problems.
In some children, particularly adolescent girls, the excessive weight gain has a serious psychological effect; their morale and self-confidence are undermined and they may become withdrawn and depressed. This problem, when added to those of adolescence itself and epilepsy, may be catastrophic. Loss of hair is also very disturbing, especially for girls; it is helpful to be able to reassure them and their parents that this will not persist.
Nocturnal enuresis does not seem to have been reported as a side effect; again it is helpful to be able to give an optimistic prognosis for this problem.
There could be positive therapeutic implications for the effect of sodium valproate on appetite and weight gain in, for example, anorexia nervosa if it were possible to recognise in advance the 44%,' of patients who show this side effect.
We are grateful to Dr M Preece for helpful discussion, Dr B D Lake for the microscopical examination of hair from some of the children, and Miss Damsari Silva for typing the manuscript. It is common practice for original articles in medical journals to give an address for reprint requests. Often authors receive many requests, usually from abroad. Since photocopiers are now freely available in most parts of the world we were interested in the true relevance of reprint requests and canvassed the views of other doctors.
Methods and results
We sent a questionnaire to 280 doctors of grade senior registrar or lecturer and above working in all specialties in the teaching hospitals in Nottingham; 161 replies were received and analysed. The doctors replying included 46 senior registrars and lecturers (31 %), 89 consultants and senior lecturers (60%), and 13 professors and readers (9 %); 13 did not specify rank. Of these respondents, 57 (35 %) published one or no medical papers each year, 87 (54%) published two to five papers, and 17 (11 %) published more than five each year. Taking each doctor's estimate together it appeared that nearly 10 800 reprint requests had been received by them in the past year.
The figure) . This maintained the PTR at or near the therapeutic range. At no time did he bleed. The initial plasma concentration of warfarin and metabolites, measured by fluorimetry,' was raised at 44 ,umol/l (13-5 tLg/ml) (figure) but subsequently
